{"nctId":"NCT02161146","briefTitle":"AGN-229666 Ophthalmic Solution in Japanese Patients With Allergic Conjunctivitis","startDateStruct":{"date":"2014-06-04","type":"ACTUAL"},"conditions":["Conjunctivitis, Allergic"],"count":240,"armGroups":[{"label":"AGN-229666","type":"EXPERIMENTAL","interventionNames":["Drug: AGN-229666"]},{"label":"Vehicle","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Vehicle to AGN-229666"]},{"label":"Olopatadine","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Olopatadine"]},{"label":"AGN-229666/Olopatadine","type":"OTHER","interventionNames":["Drug: AGN-229666","Drug: Olopatadine"]},{"label":"AGN-229666/Vehicle","type":"OTHER","interventionNames":["Drug: AGN-229666","Drug: Vehicle to AGN-229666"]}],"interventions":[{"name":"AGN-229666","otherNames":[]},{"name":"Vehicle to AGN-229666","otherNames":[]},{"name":"Olopatadine","otherNames":["PatanolÂ®"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n-Japanese patients living in Japan with a history of allergic conjunctivitis.\n\nExclusion Criteria:\n\n* Presence of active eye infection (bacterial, viral, or fungal)\n* History of an eye herpetic infection.","healthyVolunteers":false,"sex":"ALL","minimumAge":"20 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Ocular Itching Score","description":"Ocular itching was assessed by the participant 8 hours after AGN-229666 and vehicle administration and 4 hours after olopatadine administration, 5 minutes post allergen challenge using a 0 to 4 scale with 0.5 grade increments where: 0=none (no itching) to 4.0=incapacitating itch with an irresistible urge to rub (worst). Data from Days 1 and 15 were pooled together and averaged.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.33","spread":"0.523"},{"groupId":"OG001","value":"1.48","spread":"0.904"},{"groupId":"OG002","value":"0.29","spread":"0.411"}]}]}]},{"type":"SECONDARY","title":"Conjunctival Hyperemia Score","description":"Hyperemia is the engorgement of the blood vessels (redness) of the eye. Ocular hyperemia was evaluated by the investigator 8 hours after AGN-229666 and vehicle administration and 4 hours after olopatadine administration, 15 minutes post allergen challenge using a 0 to 4 scale with 0.5 grade increments where: 0=none (no hyperemia) to 4.0=extremely severe (large, numerous dilated blood vessels characterized by severe deep red color). Data from Days 1 and 15 were pooled together and averaged.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.15","spread":"0.771"},{"groupId":"OG001","value":"1.61","spread":"0.820"},{"groupId":"OG002","value":"1.34","spread":"0.849"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":0,"n":47},"commonTop":["Oropharyngeal discomfort","Oropharyngeal pain","Nasopharyngitis","Rhinorrhoea"]}}}